Back to Search
Start Over
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.
- Source :
- National Science Review; Aug2021, Vol. 8 Issue 8, p1-11, 11p
- Publication Year :
- 2021
-
Abstract
- Mutations and transient conformational movements of the receptor binding domain (RBD) that make neutralizing epitopes momentarily unavailable present immune escape routes for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To mitigate viral escape, we developed a cocktail of neutralizing antibodies (NAbs) targeting epitopes located on different domains of spike (S) protein. Screening of a library of monoclonal antibodies generated from peripheral blood mononuclear cells of COVID-19 convalescent patients yielded potent NAbs, targeting the N-terminal domain (NTD) and RBD domain of S, effective at nM concentrations. Remarkably, a combination of RBD-targeting NAbs and NTD-binding NAbs, FC05, enhanced the neutralization potency in cell-based assays and an animal model. Results of competitive surface plasmon resonance assays and cryo-electron microscopy (cryo-EM) structures of antigen-binding fragments bound to S unveil determinants of immunogenicity. Combinations of immunogens, identified in the NTD and RBD of S, when immunized in rabbits and macaques, elicited potent protective immune responses against SARS-CoV-2. More importantly, two immunizations of this combination of NTD and RBD immunogens provided complete protection in macaques against a SARS-CoV-2 challenge, without observable antibody-dependent enhancement of infection. These results provide a proof of concept for neutralization-based immunogen design targeting SARS-CoV-2 NTD and RBD. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20955138
- Volume :
- 8
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- National Science Review
- Publication Type :
- Academic Journal
- Accession number :
- 151912131
- Full Text :
- https://doi.org/10.1093/nsr/nwab053